The discovery of new small molecule-based inhibitors is an attractive field in medicinal chemistry. Structurally diversified heterocyclic derivatives have been investigated to combat multi-drug resistant bacterial infections and they offers several mechanism of action. Methicillin-resistant (MRSA) is becoming more and more deadly to humans because of its simple method of transmission, quick development of antibiotic resistance, and ability to cause hard-to-treat skin and filmy diseases. The sulfur (S) particularly sulfonyl and sulfonamide based heterocyclic moieties, have found to be good anti-MRSA agents. The development of new nontoxic, economical and highly active sulfur (S) containing derivatives has become hot research topics in drug discovery research. Presently, more than 150 FDA approved Sulfur (S)-based drugs are available in the market, and they are widely used to treat various types of diseases with different therapeutic potential. The present collective data provides the latest advancements in Sulfur (S)-hybrid compounds as antibacterial agents against MRSA. It also examines the outcomes of and investigations, exploring potential mechanisms of action and offering alternative perspectives on the structure–activity relationship (SAR). Sulfur (S)-hybrids exhibits synergistic effects with existing drugs to provide antibacterial action against MRSA

中文翻译：

---

含硫 (SⅥ) 杂环杂化物作为抗甲氧西林金黄色葡萄球菌 (MRSA) 及其 SAR 的抗菌剂

新型小分子抑制剂的发现是药物化学中一个有吸引力的领域。结构多样化的杂环衍生物已被研究用于对抗多重耐药细菌感染，并且它们提供了多种作用机制。耐甲氧西林金黄色葡萄球菌（MRSA）因其传播方式简单、抗生素耐药性发展迅速以及能够引起难以治疗的皮肤病和薄膜性疾病而对人类变得越来越致命。已发现硫(S)，特别是基于磺酰基和磺酰胺的杂环部分是良好的抗MRSA试剂。开发新型无毒、经济、高活性的含硫(S)衍生物已成为药物发现研究的热点。目前，市场上已有超过150种FDA批准的硫基药物，广泛用于治疗各种类型的疾病，具有不同的治疗潜力。目前的集体数据提供了硫 (S) 杂化化合物作为抗 MRSA 抗菌剂的最新进展。它还检查了结果和调查，探索了潜在的作用机制，并提供了关于结构-活性关系（SAR）的替代观点。硫 (S) 杂化物与现有药物具有协同作用，可提供针对 MRSA 的抗菌作用